A report of 9 multiple myeloma patients with extramedullary and extraosseous plasmocytoma and literature review
10.3760/cma.j.issn.1009-9921.2008.05.010
- VernacularTitle:伴有骨骼以外髓外浆细胞瘤的多发性骨髓瘤九例并文献复习
- Author:
Wen GAO
;
Wenming CHEN
;
Shilun CHEN
- Publication Type:Journal Article
- Keywords:
Extramedullary plasmocytoma;
Multiple myeloma
- From:
Journal of Leukemia & Lymphoma
2008;17(5):346-347,350
- CountryChina
- Language:Chinese
-
Abstract:
Objective Extramedullary plagmocytoma at diagnose or during the course of multiple myeloma is rare.In order to know this entity better and explore new therapy for it,by combining with literature review,we conducted a retrospective study to describe the clinical and laboratory features of this entity and the outcome of these manirestation.Methods From January 2001 to July 2007,123 multiple myeloma patients were treated in our hospital.We analysed the clinical features of patients with extramedullary plagmocytoma at diagnose or during the course of multiple myeloma.The response to therapy was evaluated according to the EBMT criteria.Results 9 eligible patients out of 123 with MM were retrieved from the hematology department of Beijing Chaoyang hospital.The median age was 55(range:48～66)with a female/male ratio of 1/8.One patients was found to have Extramedullary and extraosseous tumor at the time of MM diagnose,and eight patients developed Extramedullary tumor during the course of the disease.Multiple sites were usually involved.Resistance to traditional chemotherapy wag frequent.With a median follow-up of 19 months(range:3～47),2 patients are alive.Median time from progression of disease to diagnose of Extramedullary disease was 4 and a half months.The median interval from diagnosis of Extramedullary disease to death was 2 months and OS was 23 months.Conclusion Extramedullary plasmocytoma is a rare manifestation of MM,with a cumulative incidence of 7.3% of MM in our department.Multiple sites are usually involved.The resistance to the traditional chemotherapy is frequent and the prognosis is very poor.The new therapy is necessarily explored.
